Statins and their potential targets in multiple sclerosis therapy

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 5, 2003, Pages 613-622

  Stüve, Olaf ^a   Prod'homme, Thomas ^b   Slavin, Anthony ^c   Youssef, Sawsan ^d   Dunn, Shannon ^d   Steinman, Lawrence ^d   Zamvil, Scott S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSERM   (France)

^c AMGEN INC   (United States)

^d NONE

Author keywords

3 hydroxy 3 methyglutaryl coenzyme A (HMG CoA) reductase inhibitors; Experimental autoimmune encephalomyelitis (EAE); Inflammation; Multiple sclerosis (MS); Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AUTOANTIGEN; BETA INTERFERON; CD4 ANTIGEN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOMODULATING AGENT; MATRIX METALLOPROTEINASE; MEVINOLIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; CELL TYPE; CLINICAL TRIAL; COMPETITIVE INHIBITION; DEMYELINATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GLIOSIS; HUMAN; IMMUNOPATHOGENESIS; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTE MIGRATION; MULTIPLE SCLEROSIS; MYOPATHY; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PATIENT MONITORING; RAT; REVIEW; RHABDOMYOLYSIS; SENSORY NEUROPATHY; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION;

EID: 10744228682     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.5.613     Document Type: Review

References (105)

1. ANDERSON DW, ELLENBERG JH, LEVENTHAL CM, REINGOLD SC, RODRIGUEZ M, SILBERBERG DH: Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. (1992) 31:333-336.
2. STEINMAN L: Multiple sclerosis: a two-stage disease. Nat. Immunol. (2001) 2:762-764.
3. LUBLIN FD, REINGOLD SC: Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1997) 48:572-574.
4. ARNASON BG: Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol. Clin. (1983) 1:765-782.
5. RAINE CS: Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab. Invest. (1984) 50:608-635.
6. MARTIN R, MCFARLAND HF, MCFARLIN DE: Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. (1992) 10:153-187.
7. WHITACRE CC: Sex differences in autoimmune disease. Nat. Immunol. (2001) 2:777-780.
8. MARTYN CN: The epidemiology of multiple sclerosis. In: McAlpine's Multiple Sclerosis. WB Matthews (Ed.), Churchhill Livingstone, New York (1991).
9. SADOVNICK AD, EBERS GC: Epidemiology of multiple sclerosis: a critical overview. Can. J. Neurol. Sci. (1993) 20:17-29.
10. HAINES JL, TER MINASSIAN M, BAZYK A et al.: A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. (1996) 13:469-471.
11. SAWCER S, JONES HB, FEAKES R et al.: A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. (1996) 13:464-468.
12. BARCELLOS LF, OKSENBERG JR, BEGOVICH AB et al.: HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. (2003) 72:710-716.
13. HAINES JL, BRADFORD Y, GARCIA ME et al.: Multiple susceptibility loci for multiple sclerosis. Hum. Mol. Genet. (2002) 11:2251-2256.
14. SAWCER S, MARANIAN M, SETAKIS E et al.: A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain (2002) 125:1337-1347.
15. CORSINI A, BELLOSTA S, BAETTA R, FUMAGAILI R, PAOLETTI R, BERNINI F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol, Ther. (1999) 84:413-428.
16. LAROSA JC, HE J, VUPPUTURI S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 282:2340-2346.
17. NO AUTHORS LISTED: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
18. JUKEMA JW, BRUSCHKE AV, VAN BOVEN AJ et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation (1995) 91:2528-2540.
19. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333:1301-1307.
20. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335:1001-1009.
21. HERD JA, BALLANTYNE CM, FARMER JA et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. (1997) 80:278-286.
22. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615-1622.
23. NO AUTHORS LISTED: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339:1349-1357.
24. RIEGGER G, ABLETSHAUSER C, LUDWIG M et al.: The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis (1999) 144:263-270.
25. PITT B, WATERS D, BROWN WV et al.: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N. Engl. J. Med. (1999) 341:70-76.
26. ISTVAN ES, DEISENHOFER J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science (2001) 292:1160-1164.
27. GINSBERG HN: Effects of statins on triglyceride metabolism. Am. J. Cardiol. (1998) 81:B32-B35.
28. DAIN JG, FU E, GORSKI J, NICOLETTI J, SCALLEN TJ: Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. (1993) 21:567-572.
29. CHRISTIANS U, JACOBSEN W, FLOREN LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. (1998) 80:1-34.
30. BLACK DM, BAKKER-ARKEMA RG, NAWROCKI JW: An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch. Intern. Med. (1998) 158:577-584.
31. DAVIDSON MH: Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs (2001) 61:197-206.
32. CHARIOT P, ABADIA R, AGNUS D, DANAN C, CHARPENTIER C, GHERARDI RK: Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med. (1993) 94:109-110.
33. HUNG YT, YEUNG VT: Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis. Hong Kong Med. J. (2000) 6:423-424.
34. HODEL C: Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol, Lett. (2002) 128:159-168.
35. STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. (2002) 346:539-540.
36. GAIST D, GARCIA RODRIGUEZ LA, HUERTA C, HALLAS J, SINDRUP SH: Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur. J. Clin. Pharmacol. (2001) 56:931-933.
37. GAIST D, JEPPESEN U, ANDERSEN M, GARCIA RODRIGUEZ LA, HALLAS J, SINDRUP SH: Statins and risk of polyneuropathy: a case-control study. Neurology (2002) 58:1333-1337.
38. LIAO JK: Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. (2002) 110:285-288.
39. GLOMSET JA, GELB MH, FARNSWORTH CC: Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem. Sci. (1990) 15:139-142.
40. MALTESE WA: Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. (1990) 4:3319-3328.
41. VAN AELST L, D'SOUZA-SCHOREY C: Rho GTPases and signaling networks. Genes Dev. (1997) 11:2295-2322.
42. TOLEDANO JE, PARTRIDGE NC: Statins: not just for cholesterol? Trends Endocrinol. Metab. (2000) 11:255-256.
43. GREENWOOD J, WALTERS CE, PRYCE G et al.: Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. (2003) 17:905-907.
44. BELLOSTA S, FERRI N, BERNINI F, PAOLETTI R, CORSINI A: Non-lipid-related effects of statins. Ann. Med. (2000) 32:164-176.
45. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
46. KOBASHIGAWA JA, KATZNELSON S, LAKS H et al.: Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. (1995) 333:621-627.
47. WEITZ-SCHMIDT G: Statins as anti-inflammatory agents. Trends Pharmacol. Sci. (2002) 23:482-486.
48. STUVE O, YOUSSEF S, STEINMAN L, ZAMVIL SS: Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. (2003) 16:393-401.
49. PAHAN K, SHEIKH FG, NAMBOODIRI AM, SINGH I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest (1997) 100:2671-2679.
50. STANISLAUS R, PAHAN K, SINGH AK, SINGH I: Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. (1999) 269:71-74.
51. STANISLAUS R, SINGH AK, SINGH I: Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. (2001) 66:155-162.
52. H2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 420:78-84.
53. H1 cells through atorvastatin. J. Exp. Med. (2003) 197:725-733.
54. ZAMVIL SS, STEINMAN L: The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. (1990) 8:579-621.
55. WEKERLE H, LININGTON C, LASSMANN H, MEYERMANN R: Cellular immune reactivity within the CNS. Trends Neurosci. (1986) 9:271-277.
56. HICKEY WF, HSU BL, KIMURA H: T-lymphocyte entry into the central nervous system. J. Neurosci. Res. (1991) 28:254-260.
57. HICKEY WF: Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. (1991) 1:97-105.
58. MACH B, STEIMLE V, MARTINEZHSORIA E, REITH W: Regulation of MHC Class II genes: lessons from a disease. Annu. Rev. Immunol. (1996) 14:301-331.
59. CHANG CH, FLAVELL RA: Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J. Exp. Med. (1995) 181:765-767.
60. MUHLETHALER-MOTTET A, OTTEN LA, STEIMLE V, MACH B: Expression of MHC Class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. (1997) 16:2851-2860.
61. PISKURICH JF, WANG Y, LINHOFF MW, WHITE LC, TING JP: Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-γ, STAT1, and TGF-β-regulated expression of the class II transactivator gene. J. Immunol. (1998) 160:233-240.
62. SOOS JM, MORROW J, ASHLEY TA, SZENTE BE, BIKOFF EK, ZAMVIL SS: Astrocytes express elements of the Class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J. Immunol. (1998) 161:5959-5966.
63. DONG Y, ROHN WM, BENVENISTE, EN: IFN-γ regulation of the Type IV Class II transactivator promoter in astrocytes. J. Immunol. (1999) 162:4731-4739.
64. O'KEEFE GM, NGUYEN VT, BENVENISTE EN: Class II transactivator and Class II MHC gene expression in microglia: modulation by the cytokines TGF-β, IL-4, IL-13 and IL-10. Eur. J. Immunol. (1999) 29:1275-1285.
65. KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399-1402.
66. DUSTIN ML, SHAW AS: Costimulation: building an immunological synapse. Science (1999) 283:649-650.
67. GRAKOUI A, BROMLEY SK, SUMEN C et al.: The immunological synapse: a molecular machine controlling T cell activation. Science (1999) 285:221-227.
68. SPRINGER TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 76:301-314.
69. SPRINGER TA: Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol (1995) 57:827-872.
70. BAJETTO A, BONAVIA R, BARBERO S, SCHETTINI G: Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J. Neurochem. (2002) 82:1311-1329.
71. OLSON TS, LEY K: Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comput. Physiol. (2002) 283:R7-R28.
72. REZAIE P, TRILLO-PAZOS G, EVERALL IP, MALE DK: Expression of β-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Glia (2002) 37:64-75.
73. COLUMBA-CABEZAS S, SERAFINI B, AMBROSINI E et al.: Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. (2002) 130:10-21.
74. AMBROSINI E, COLUMBA-CABEZAS S, SERAFINI B, MUSCELLA A, ALOISI F: Astrocytes are the major intracerebral source of macrophage inflammatory protein-3α/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia (2003) 41:290-300.
75. KENNEDY KJ, STRIETER RM, KUNKEL SL, LUKACS NW, KARPUS WJ: Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1. J. Neuroimmunol. (1998) 92:98-108.
76. ROMANO M, DIOMEDE L, SIRONI M et al.: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. (2000) 80:1095-1100.
77. SPRINGER TA, ANDERSON DC: The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis, and migration into inflammatory sites: insights from an experiment of nature. Ciba Found. Symp. (1986) 118:102-126.
78. WAWRYK SO, NOVOTNY JR, WICKS IP et al.: The role of the LEA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol. Rev. (1989) 108:135-161.
79. LEE SJ, BENVENISTE EN: Adhesion molecule expression and regulation on cells of the central nervous system. J. Neuroimmunol. (1999) 98:77-88.
80. SOBEL RA, MITCHELL ME, FONDREN G: Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am. J. Pathol. (1990) 136:1309-1316.
81. WASHINGTON R, BURTON J, TODD RF et al.: Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann. Neurol. (1994) 35:89-97.
82. BROSNAN CF, CANNELLA B, BATTISTINI L, RAINE CS: Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology (1995) 45:S16-S21.
83. CANNELLA B, RAINE CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. (1995) 37:424-435.
84. 2 integrin LFA-1 in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. (1996) 55:1060-1072.
85. FROHMAN EM, FROHMAN TC, DUSTIN ML et al.: The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-γ, tumor necrosis factor α, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation. J. Neuroimmunol. (1989) 23:117-124.
86. MOINGEON P, CHANG HC, WALLNER BP, STEBBINS C, FREY AZ, REINHERZ EL: CD2-mediated adhesion facilitates T lymphocyte antigen recognition function. Nature (1989) 339:312-314.
87. KALLEN J, WELZENBACH K, RAMAGE P et al.: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. (1999) 292:1-9.
88. YONG VW, POWER C, FORSYTH P, EDWARDS DR: Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. (2001) 2:502-511.
89. HOWARD L, GLYNN P: Membrane-associated metalloproteinase recognized by characteristic cleavage of myelin basic protein: assay and isolation. Methods Enzymol. (1995) 248:388-395.
90. BELLOSTA S, VIA D, CANAVESI M et al.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1671-1678.
91. GANNE F, VASSE M, BEAUDEUX JL et al.: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb. Haemost. (2000) 84:680-688.
92. ABBAS AK, MURPHY KM, SHER A: Functional diversity of helper T lymphocytes. Nature (1996) 383:787-793.
93. H2 cells in neurologic disorders. Chem. Immunol. (1996) 63:171-186.
94. KHOURY SJ, HANCOCK WW, WEINER HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. (1992) 176:1355-1364.
95. BEGOLKA WS, VANDERLUGT CL, RAHBE SM, MILLER SD: Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. (1998) 161:4437-4446.
96. PANITCH HS, HIRSCH RL, HALEY AS, JOHNSON KP: Exacerbations of multiple sclerosis in patients treated with γ interferon. Lancet (1987) 1:893-895.
97. LIU JS, ZHAO, ML, BROSNAN CF, LEE SC: Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. (2001) 158:2057-2066.
98. KAWAHARA K, GOTOH T, OYADOMARI S et al.: Co-induction of argininosuccinate synthetase, cationic amino acid transporter-2, and nitric oxide synthase in activated murine microglial cells. Brain Res. Mol. Brain Res. (2001) 90:165-173.
99. NOMURA Y: NF-κB activation and IκBα dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci. (2001) 68:1695-1701.
100. NEUHAUS O, STRASSER-FUCHS S, FAZEKAS F et al.: Statins as immunomodulators: comparison with interferon-β 1b in MS. Neurology (2002) 59:990-997.
101. VOLLMER T, DURKALSKI V, TYOR W et al.: An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS). American Academy of Neurology 55th Annual Meeting Program S11.(2003) 004. Abstract.
102. H2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. (2000) 105:967-976.
103. STUVE O, DOOLEY NP. UHM JH et al.: Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. (1996) 40:853-863.
104. LEPPERT D, WAUBANT E, BURK MR, OKSENBERG JR, HAUSER SL: Interferon β-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. (1996) 40:846-852.
105. STUVE O, CHABOT S, JUNG SS, WILLIAMS G, YONG VW: Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon β-1b through an effect on matrix metalloproteinase-9. J. Neuroimmunol. (1997) 80:38-46.